TRIM21 and systemic sclerosis: To our knowledge, previous studies have not evaluated whether the presence of anti-Ro52 predicts progression of SSc-ILD, although one study demonstrated that anti-Ro52-positivity is associated with worse survival in patients with SSc [20].